Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

DISEASE CHARACTERISTICS:

* Histologically confirmed ovarian epithelial carcinoma, primary peritoneal cavity carcinoma, or epithelial carcinoma of the fallopian tubes, meeting 1 of the following criteria:

  * Stage III or IV disease that was treated with initial therapy comprising a standard platinum-containing regimen

    * Must have \< 2 cm of residual disease with no evidence of disease progression after initial chemotherapy AND have no disease progression immediately prior to stem cell collection
    * Patients initially presenting with stage IV disease who have achieved a clinical response (complete response \[CR\] or partial response \[PR\]) after initial therapy are eligible
  * Responding recurrent disease

    * Patients who have had recurrence with elevated CA 125 levels (\> 100 U/mL) and who have achieved a reduction of CA 125 level by 50% for 4 weeks following the most recent course of reinduction chemotherapy are eligible
    * Patients who have achieved a CR or PR after salvage chemotherapy for relapsed disease are eligible
* Patients with measurable or evaluable disease must have achieved a PR after prior therapy
* No clinically significant pleural effusions

PATIENT CHARACTERISTICS:

* Karnofsky performance status 70-100%
* ANC \> 1,000/μL
* Platelet count \> 100,000/μL
* Serum bilirubin \< 1.5 mg/dL
* SGOT and SGPT ≤ 2.5 times normal
* Creatinine clearance ≥ 60 mL/min
* No active cardiac disease that, in the opinion of the investigator, would preclude safe administration of chemotherapy
* Cardiac ejection fraction normal at rest by MUGA
* No history of potentially disabling psychiatric disorders
* Hepatitis B antigen, hepatitis C antibody, and HIV antibody negative
* No clinically significant peripheral neuropathy
* FEV\_1 ≥ 2.0 L or ≥ 75% of the lower limit of normal

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* At least 4 weeks since prior chemotherapy or radiotherapy
* No prior radiotherapy to the whole abdomen